Raltitrexed
Raltitrexed is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against thymidylate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
83 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 4 | 22 | 3 | 2 | 1 | 30 |
| Carcinoma | D002277 | — | C80.0 | 1 | 9 | 4 | 1 | 5 | 19 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 6 | 5 | 1 | 5 | 18 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | 1 | 1 | 2 | 6 |
| Colonic neoplasms | D003110 | — | C18 | — | 3 | — | 1 | 1 | 5 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | 1 | 1 | 1 | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | 1 | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 7 | 3 | — | 5 | 16 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 5 | 1 | — | — | 6 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | 1 | — | — | 3 |
| Malignant mesothelioma | D000086002 | — | — | 1 | 2 | 1 | — | — | 3 |
| Mesothelioma | D008654 | — | C45 | 1 | 2 | 1 | — | — | 3 |
| Therapeutic chemoembolization | D016461 | — | — | — | 1 | 1 | — | — | 2 |
| Peritoneal neoplasms | D010534 | — | — | — | — | 1 | — | — | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | — | — | 8 | — | — | — | 8 |
| Recurrence | D012008 | — | — | 1 | 4 | — | — | — | 5 |
| Neoplasms | D009369 | — | C80 | 3 | 1 | — | — | — | 4 |
| Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 2 |
| Esophageal neoplasms | D004938 | — | C15 | — | 2 | — | — | — | 2 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 1 | — | — | 1 | 2 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
| Hyperthermic intraperitoneal chemotherapy | D000084262 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Raltitrexed |
| INN | raltitrexed |
| Description | Raltitrexed (Thaltitrexed, Tomudex, TDX, ZD 1694) is an antimetabolite drug used in cancer chemotherapy. It is an inhibitor of thymidylate synthase, and is manufactured by AstraZeneca.
|
| Classification | Small molecule |
| Drug class | antineoplastic thymidylate synthetase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 112887-68-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL225071 |
| ChEBI ID | 5847 |
| PubChem CID | 104758 |
| DrugBank | DB00293 |
| UNII ID | FCB9EGG971 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,236 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
478 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use